万东医疗股份回购进展公告——投资者详细解读

要点概览

• 回购方案首次披露日：2025年8月23日
• 回购实施期限：2025年8月22日至2026年8月21日
• 预计回购金额：3,000万元~6,000万元人民币
• 回购目的：用于员工持股计划或股权激励
• 累计已回购股份数量：1,802,700股
• 累计已回购股份占总股本比例：0.2564%
• 累计已回购金额：29,992,822.08元人民币
• 实际回购价格区间：15.71元/股~17.99元/股

公告详细内容解读

2025年8月22日，北京万东医疗科技股份有限公司（以下简称“万东医疗”）召开第十届董事会第十次会议，审议并通过了以集中竞价交易方式回购公司股份的方案。公司计划使用自有资金回购3,000万元至6,000万元公司股份，回购价格不超过25元/股，回购期限为12个月，回购股份将全部用于员工持股计划或股权激励。

截至2026年3月底，公司通过集中竞价交易方式累计回购1,802,700股，已回购股份占公司总股本的0.2564%。已支付回购总金额为29,992,822.08元，实际回购价格区间在15.71元/股至17.99元/股之间。值得注意的是，该回购方案并未触及减少注册资本、可转债转换或纯粹维护公司价值等其他用途，明确仅用于员工持股和股权激励。

公司表示，回购过程严格遵守《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引第7号——回购股份》等相关法律法规，并将根据市场情况择机实施回购，同时及时披露相关信息，提醒投资者注意投资风险。

投资者需重点关注事项

• 员工持股和股权激励： 本次回购股份明确用于员工持股计划和股权激励，有助于绑定核心员工利益，提升团队积极性和公司治理结构，可能对公司长期业绩和股价形成利好预期。
• 回购价格区间： 实际回购价格区间为15.71元/股至17.99元/股，显示公司管理层对当前股价的认可，同时也为市场提供了回购底部支撑。
• 回购进度与剩余空间： 距离回购上限仍有一定空间，未来几个月公司有可能继续加大回购力度，对市场形成持续支撑。
• 未选择注销股份： 本次回购股份不会减少总股本，而是用于激励计划，未来不会稀释现有股东持股比例，但可能带来员工持股释放后的市场波动。
• 合规性与信息披露： 公司承诺严格按照监管要求实施回购并及时信息披露，增强公司治理透明度。

潜在影响与市场敏感性分析

本次股份回购进展公告对公司股价具备潜在推动作用。因股份回购体现公司对自身价值的信心，且用于员工激励，有助于稳定核心团队，提升经营效率，市场往往视为正面信号。此外，明确的回购价格区间为股价提供一定安全边际，未来如公司继续推进回购计划，可能进一步支撑或提振股价表现。投资者应关注后续回购进展及相关信息披露。

免责声明： 本文仅为信息披露公告的综合解读，不构成任何投资建议。投资者应结合自身风险承受能力和市场情况，审慎作出投资决策。公司公告及相关信息请以上海证券交易所官网披露为准。

Wandong Medical Share Buyback Progress Announcement — Investor Detailed Interpretation

Key Points Overview

• Initial Buyback Plan Disclosure Date: August 23, 2025
• Buyback Implementation Period: August 22, 2025 – August 21, 2026
• Planned Buyback Amount: RMB 30 million to 60 million
• Buyback Purpose: Employee stock ownership plan or equity incentive
• Accumulated Shares Bought Back: 1,802,700 shares
• Accumulated Shares as % of Total Share Capital: 0.2564%
• Accumulated Buyback Amount: RMB 29,992,822.08
• Actual Buyback Price Range: RMB 15.71 – RMB 17.99 per share

Detailed Announcement Interpretation

On August 22, 2025, Beijing Wandong Medical Technology Co., Ltd. (“Wandong Medical”) held the 10th meeting of the 10th Board of Directors and approved a proposal for a share buyback via centralized bidding. The company plans to use its own funds to buy back shares worth RMB 30–60 million, with a buyback price not exceeding RMB 25 per share, within a 12-month period. All repurchased shares will be used for employee ownership or equity incentive plans.

As of the end of March 2026, the company had cumulatively repurchased 1,802,700 shares through centralized bidding, accounting for 0.2564% of its total share capital. The total amount paid for the buyback was RMB 29,992,822.08, with actual buyback prices ranging from RMB 15.71 to 17.99 per share. It is noteworthy that the repurchased shares are not for capital reduction, convertible bond conversion, or solely for maintaining company value — they are designated for employee incentives.

The company stated it would strictly comply with relevant regulations and make decisions on buybacks according to market conditions, while fulfilling information disclosure obligations and reminding investors of associated risks.

Key Issues for Investors

• Employee Ownership and Incentives: The buyback is specifically for employee stock plans and equity incentives, which can help retain and motivate core personnel, improving governance and potentially boosting long-term performance and share price.
• Buyback Price Range: The buyback price range of RMB 15.71–17.99 per share signals management’s confidence in the company’s current valuation, providing a price floor for the market.
• Buyback Progress and Remaining Capacity: With room under the plan’s upper limit, the company may continue buybacks in coming months, potentially providing ongoing market support.
• No Capital Reduction: The repurchased shares are not canceled but will be used for incentives, meaning no dilution for current shareholders, but possible market volatility when employee shares are unlocked.
• Compliance and Disclosure: The company promises strict adherence to regulations and timely disclosure, improving transparency.

Potential Impact and Market Sensitivity Analysis

This buyback progress announcement is potentially price-sensitive. Buybacks often signal management’s confidence in intrinsic value and, when used for incentives, can stabilize the workforce — both viewed positively by the market. The clear buyback price range provides a support level for the share price. Continued buyback activity could further underpin or boost the price. Investors should monitor further buyback progress and disclosures.

Disclaimer: This article is an analytical summary of an official company announcement and does not constitute investment advice. Investors should consider their own risk tolerance and market circumstances. Please refer to official disclosures on the Shanghai Stock Exchange website for authoritative information.

View 万东医疗 Historical chart here